Saxenda Cost in Pennsylvania: 2026 Prices, Insurance, and Savings Options

What Does Saxenda Actually Cost in Pennsylvania in 2026?

The manufacturer list price for Saxenda (liraglutide 3 mg) set by Novo Nordisk is $1,349 per month for a five-pen carton. That figure reflects the wholesale acquisition cost and is what uninsured patients typically see at Pennsylvania retail pharmacies. The price has remained stable since late 2024.

Retail Pharmacy Pricing Across PA

Cash-pay prices at major Pennsylvania chains (CVS, Walgreens, Rite Aid, Giant Eagle Pharmacy) cluster tightly around the $1,349 list price. Independent pharmacies occasionally price 3 to 5% lower, but meaningful discounts require insurance, a savings card, or a compounded alternative.

Why Cash Prices Stay High

Saxenda has no FDA-approved generic equivalent as of May 2026. Novo Nordisk holds the commercial monopoly on branded liraglutide 3 mg for weight management. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss versus 2.6% with placebo over 56 weeks, establishing the clinical basis for the current pricing tier 1. Without generic competition, list price reductions are unlikely in the near term.

Price Comparison: Saxenda vs. Newer GLP-1s

Saxenda's $1,349 monthly cost sits below the list prices of semaglutide 2.4 mg (Wegovy, ~$1,349) and tirzepatide (Zepbound, ~$1,059). The daily injection schedule is Saxenda's main practical disadvantage compared to once-weekly alternatives. For patients whose insurance covers Saxenda but not newer agents, the effective out-of-pocket cost may actually be lower despite the daily dosing burden.

Does Pennsylvania Medicaid Cover Saxenda?

Pennsylvania Medicaid covers Saxenda for chronic weight management, but approval requires prior authorization. The prescribing clinician must document that the patient meets FDA label criteria: a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia 2.

Prior Authorization Requirements

Pennsylvania's Medicaid managed care organizations (MCOs), including UPMC for You, AmeriHealth Caritas, Highmark Wholecare, and Aetna Better Health of PA, each maintain their own PA criteria. Common documentation requirements include:

• A recorded BMI within the qualifying range from the past 90 days
• Evidence that the patient has attempted lifestyle modification (diet and exercise) for at least 3 to 6 months
• Documentation of at least one weight-related comorbidity for patients with BMI 27 to 29.9
• A treatment plan that includes ongoing nutritional counseling

Approval Timelines

Standard PA decisions from Pennsylvania Medicaid MCOs typically arrive within 72 hours. Urgent requests can be expedited to 24 hours. If denied, patients have the right to appeal through both the MCO's internal review and the Pennsylvania Department of Human Services fair hearing process.

Which Commercial Insurance Plans Cover Saxenda in PA?

Coverage varies widely among Pennsylvania's commercial insurers. Several of the state's largest carriers include Saxenda on their formularies, though nearly all require prior authorization and place it on a specialty or non-preferred brand tier.

Plans With Known Saxenda Coverage

Highmark Blue Cross Blue Shield (PA's largest commercial insurer), UPMC Health Plan, Independence Blue Cross, Geisinger Health Plan, and Capital Blue Cross have all covered Saxenda under select plan designs. Employer-sponsored plans within these networks may differ from individual marketplace plans, so checking the specific formulary is necessary.

Typical Copay Ranges

For commercially insured patients with Saxenda on formulary, tier 3 (non-preferred brand) copays in Pennsylvania commonly range from $75 to $150 per month. Specialty tier placement can push cost-sharing to 25 to 40% of the negotiated price, potentially exceeding $300 per month before savings card application.

Plans That Commonly Exclude Weight-Loss Drugs

Some self-insured employer plans and certain small-group market plans in Pennsylvania explicitly exclude anti-obesity medications from coverage. Medicare Part D does not cover Saxenda for weight loss, a federal exclusion that affects approximately 2.4 million Pennsylvania Medicare beneficiaries. "Anti-obesity medications remain a statutory exclusion under Medicare Part D," according to the Centers for Medicare & Medicaid Services formulary guidance 3.

How the Novo Nordisk Savings Card Works in Pennsylvania

The Novo Nordisk savings card is the single most effective tool for reducing Saxenda costs for commercially insured Pennsylvania residents. Eligible patients can pay as little as $25 per 30-day prescription fill.

Eligibility Criteria

The savings card is available to patients who have commercial (private) insurance that covers Saxenda. Patients with government-funded insurance (Medicaid, Medicare, TRICARE, VA) are not eligible per federal anti-kickback statute requirements. Uninsured patients do not qualify for the standard savings card but may be eligible for Novo Nordisk's patient assistance program (PAP).

How to Activate

Patients can download the savings card from Novo Nordisk's website or receive it through their prescribing clinician's office. The card functions as a secondary payer at the pharmacy counter. The pharmacist runs the primary insurance first, then applies the savings card to reduce the remaining copay.

Annual Limits

The savings card carries an annual maximum benefit. Once the cap is reached (typically after 12 monthly fills), the patient reverts to their standard insurance copay for the remainder of the benefit year. Tracking usage against the annual limit prevents unexpected full-price fills.

Is Compounded Liraglutide 3 mg Legal in Pennsylvania?

Compounded liraglutide 3 mg is available through licensed 503A compounding pharmacies in Pennsylvania. This option exists because liraglutide itself is not patented (the patents cover Saxenda's specific formulation and device), and 503A pharmacies can compound medications pursuant to individual prescriptions under Section 503A of the Federal Food, Drug, and Cosmetic Act 4.

503A vs. 503B Pharmacies

503A pharmacies compound individual prescriptions based on a specific patient-prescriber relationship. 503B outsourcing facilities can produce larger batches without individual prescriptions. Both operate in Pennsylvania, though 503A pharmacies are more commonly used for liraglutide compounding. The Pennsylvania State Board of Pharmacy oversees state-level compliance for both categories.

Pricing for Compounded Liraglutide

Compounded liraglutide 3 mg pricing in Pennsylvania varies by pharmacy but is substantially lower than brand Saxenda. Some 503A pharmacies advertise monthly costs between $150 and $450, depending on concentration, vial size, and whether the patient self-injects from a vial or uses a pen device. These prices represent savings of 67 to 89% compared to brand Saxenda's list price.

Quality and Safety Considerations

Compounded medications do not undergo FDA premarket review. The potency, sterility, and stability of compounded liraglutide depend entirely on the compounding pharmacy's quality controls. Patients should verify that their pharmacy holds current Pennsylvania Board of Pharmacy licensure and, ideally, voluntary accreditation from the Pharmacy Compounding Accreditation Board (PCAB).

Can You Get Saxenda via Telehealth in Pennsylvania?

Pennsylvania permits telehealth prescribing of Saxenda. State law allows clinicians to establish a patient-provider relationship through synchronous audio-video visits, and controlled substance restrictions do not apply to Saxenda since GLP-1 receptor agonists are not scheduled drugs.

How Telehealth Prescribing Works

A licensed prescriber (physician, nurse practitioner, or physician assistant) conducts a video consultation, reviews the patient's medical history and BMI, and, if clinically appropriate, sends an electronic prescription to the patient's preferred Pennsylvania pharmacy. Follow-up visits for dose titration and monitoring can also occur via telehealth.

Telehealth Platform Options

Multiple telehealth platforms serve Pennsylvania patients seeking Saxenda prescriptions. Some specialize in weight management and bundle the consultation fee, prescription, and medication delivery into a single monthly price. Others provide the prescription only, leaving the patient to fill it at a local pharmacy or mail-order service. Comparing total cost (consultation plus medication) rather than consultation fee alone gives a more accurate picture.

Insurance and Telehealth

Pennsylvania law requires commercial insurers to cover telehealth visits on parity with in-person visits. A Saxenda prescription written during a telehealth encounter is processed identically to one from an office visit. The Novo Nordisk savings card applies regardless of whether the prescription originated from a telehealth or in-person appointment.

Saxenda Dose Titration and Its Effect on Monthly Cost

Saxenda uses a five-week dose escalation schedule: 0.6 mg daily for week 1, 1.2 mg for week 2, 1.8 mg for week 3, 2.4 mg for week 4, and the maintenance dose of 3.0 mg from week 5 onward 2. During the titration period, each pen lasts longer than at maintenance dose, meaning the first month's supply stretches further.

Pen Math

Each Saxenda pen contains 18 mg of liraglutide. At the 3.0 mg maintenance dose, one pen lasts 6 days. A five-pen carton lasts 30 days. During week 1 at 0.6 mg per day, a single pen lasts 30 days. This means patients filling their first carton during titration may not need a refill for 6 to 8 weeks, effectively halving the initial monthly cost.

Titration Tips for Cost Savings

Some clinicians write the first Saxenda prescription for a single carton and schedule the refill based on actual consumption during titration rather than a fixed 30-day supply. This approach prevents waste and delays the second fill. Patients should not adjust the titration schedule solely to save money. The graduated dosing exists to minimize gastrointestinal side effects (nausea affects approximately 39% of patients in clinical trials) 1.

Other Discount Programs and Assistance in Pennsylvania

Beyond the manufacturer savings card, several additional pathways can reduce Saxenda costs for Pennsylvania residents.

Novo Nordisk Patient Assistance Program (PAP)

Uninsured patients with household income at or below 400% of the federal poverty level may qualify for free Saxenda through Novo Nordisk's PAP. Applications require proof of income, residency, and a valid prescription. Approval typically takes 2 to 4 weeks.

Pharmacy Discount Cards (GoodRx, RxSaver, SingleCare)

Third-party discount cards sometimes reduce cash prices by 5 to 15% at participating Pennsylvania pharmacies. These discounts are modest relative to Saxenda's high list price and cannot be combined with insurance or the manufacturer savings card. They are most useful for uninsured patients who do not qualify for the PAP.

340B Program Pharmacies

Pennsylvania patients receiving care at federally qualified health centers (FQHCs) or other 340B-eligible entities may access Saxenda at significantly reduced cost. The 340B Drug Pricing Program requires manufacturers to provide outpatient drugs at discounted prices to eligible healthcare organizations. Pennsylvania has over 200 340B-covered entities.

Clinical Efficacy: What You Get for the Cost

Cost decisions should factor in expected outcomes. The SCALE Obesity and Prediabetes trial randomized 3,731 adults without diabetes to liraglutide 3 mg or placebo alongside lifestyle counseling. At 56 weeks, the liraglutide group lost a mean of 8.0% of body weight compared to 2.6% in the placebo group. Sixty-three percent of the liraglutide group lost at least 5% body weight versus 27% with placebo 1.

Durability of Weight Loss

The SCALE trial's 3-year extension data showed that patients who continued liraglutide 3 mg maintained weight loss, while those switched to placebo regained most of the lost weight within 12 months 5. This finding has direct cost implications: Saxenda is designed as a long-term therapy, not a short-course treatment.

Comparison to Semaglutide 2.4 mg

The STEP-1 trial (N=1,961) demonstrated 14.9% mean weight loss with semaglutide 2.4 mg versus 2.4% with placebo at 68 weeks 6. Semaglutide 2.4 mg produces roughly twice the weight loss of liraglutide 3 mg. For patients whose insurance covers both drugs at similar copay tiers, semaglutide is the more cost-effective choice per kilogram lost. For patients with Saxenda coverage but no semaglutide coverage, Saxenda remains a clinically validated option with an established 10-year safety record.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI ≥30 or BMI ≥27 with comorbidities, noting that "the choice among available agents should consider efficacy, side-effect profile, patient preference, and cost" 7.